Document is current

Article History

Received: 3 December 2020

Accepted: 2 February 2021

First Online: 1 March 2021

Change Date: 23 May 2021

Change Type: Update

Change Details: The Open Access funding by Projekt DEAL was not included in the original publication, this article has been updated.

Ethics approval and consent to participate

: The study was approved by the leading institutional ethics committee of the University of Freiburg (EK 329/20). Due to the retrospective and observational nature of the study and anonymous data evaluation, the need for informed consent was waived.

: Not applicable.

: All authors have completed the ICMJE form (available upon request from the corresponding author). FS Taccone reports personal fees from Eurosets outside the submitted work. C Benk and G Trummer are shareholders of Resuscitec GmbH and received personal fees from Resuscitec GmbH outside the submitted work. C Benk and G Trummer hold patents US 10695407 and EU 3016675 issued to Resuscitec GmbH. D Brodie reports grants from ALung Technologies, personal fees from Baxter, personal fees from Xenios, personal fees from Abiomed, and unpaid consultancy for Hemovent outside the submitted work. G Michels reports personal fees from ZOLL, Sedana Medical, Orion Pharma, and Getinge outside the submitted work; the competing interests are not related to the present work. All other authors declare no competing interests.